Rituximab
Chronic Obstructive Pulmonary Disease
Explore 22 assets in Chronic Obstructive Pulmonary Disease →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Paul Szabolcs
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03500731CT.gov Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Obstructive Pulmonary Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rituximab (this asset) | Paul Szabolcs | P1/2 | CCC · 48 |
| Liraglutide | Claus Bogh Juhl | P4 | BB |
| Roflumilast | Prince of Songkla University | P3 | BB |
| Ciprofloxacin | Chronic Obstructive Pulmonary Disease Trial Network, Denmark | P4 | BB |
| Tazobactam | Chronic Obstructive Pulmonary Disease Trial Network, Denmark | P4 | BB |
| .Alpha.-1 Protease Inhibitor | Takeda | P4 | BB |
| Piperacillin | Chronic Obstructive Pulmonary Disease Trial Network, Denmark | P4 | BB |
| 20-valent pneumococcal conjugate vaccine | University of Alabama at Birmingham | P4 | BB |
| Alvelestat | University of Alabama at Birmingham | P2 | B |
+42 more in the Chronic Obstructive Pulmonary Disease cohort
Other indications for Rituximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoblastic Lymphoma | — | P4 | BBB · 75 |
| Grade III Lymphomatoid Granulomatosis | — | P2 | BBB · 74 |
| Testicular Lymphoma | — | P2 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rituximab in Chronic Obstructive Pulmonary Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g-1-human-mouse-monoclonal-idec-c2b8-gamma1-chain-anti-human-antigen-cd-20-disulfide-with-human-mouse-monoclonal-idec-c2b8-kappa-chain-dimer-chronic-obstructive-pulmonary-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →